Novel Germline Mutations in a Cohort of Men with Familial Prostate Cancer.

Germline mutations in are associated with aggressive prostate cancer. Additional information regarding the clinical phenotype of germline pathogenic variants in other prostate cancer predisposition genes is required. Clinical testing has been limited by evidence, further restricting knowledge of variants that contribute to prostate cancer development. Prostate cancer patients who were first- and second-degree relatives from multi-case prostate cancer families underwent a gene panel screen to identify novel (non-) germline pathogenic variants in cancer predisposition genes and define clinical phenotypes associated with each gene. The germline genomic DNA (gDNA) of 94 index cases with verified prostate cancer from families with a minimum of two verified prostate cancer cases was screened with an 84-cancer-gene panel. Families were recruited for multi-case breast/ovarian cancer ( = 66), or multi-case prostate cancer ( = 28). Prostate cancer characteristics associated with each gene were compared with prostate cancer cases of confirmed non-mutation carriers (), also from multi-case prostate cancer families ( = 111), and with data from the Prostate Cancer Outcomes Registry (PCOR). Ninety-four prostate cancer index cases underwent gene panel testing; twenty-two index cases (22/94; 23%) were found to carry a class 4-5 (C4/5) variant. Six of twenty-two (27%) variants were not clinically notifiable, and seven of twenty-two (31.8%) variants were in genes. Nine of twenty-two (40.9%) index cases had variants identified in ( = 4), ( = 2) and ( = 3); gDNA for all relatives of these nine cases was screened for the corresponding familial variant. The final cohort comprised 15 confirmed germline mutation carriers with prostate cancer ( = 9, = 2, = 4). and -associated cancers were D'Amico intermediate or high risk, comparable to our previously published and prostate cancer cohort. carriers demonstrated low- to intermediate-risk prostate cancer. In the cohort, 53.2% of subjects demonstrated high-risk disease compared with 25% of the PCOR cohort. and germline mutation carriers and the (confirmed non-mutation carriers) cohort demonstrated high risk disease compared with the general population. Targeted genetic testing will help identify men at greater risk of prostate-cancer-specific mortality. Data correlating rare variants with clinical phenotype and familial predisposition will strengthen the clinical validity and utility of these results and establish these variants as significant in prostate cancer detection and management.